Literature DB >> 1703440

Serpin-serine protease binding kinetics: alpha 2-antiplasmin as a model inhibitor.

C Longstaff1, P J Gaffney.   

Abstract

We have examined in detail the kinetics of binding of the serpin alpha 2-antiplasmin to the serine proteases alpha-chymotrypsin and plasmin. These represent model systems for serpin binding. We find, in contrast to earlier published results with alpha 2-antiplasmin and plasmin, that binding is reversible, and slow binding kinetics can be observed, under appropriate conditions. Binding follows a two-step process with both enzymes, with the formation of an initial loose complex which then proceeds to a tightly bound complex. In the absence of lysine and analogues, equilibrium between alpha 2-antiplasmin and plasmin is achieved rapidly, with an overall inhibition constant (Ki') of 0.3 pM. In the presence of tranexamic acid or 6-aminohexanoic acid, lysine analogues that mimic the effects of fibrin, plasmin binding kinetics are changed such that equilibrium is reached slowly following a lag phase after mixing of enzyme and inhibitor. The Ki' is also affected, rising to 2 pM in the presence of 6-aminohexanoic acid concentrations above 15 mM. Thus extrapolation to the in vivo situation indicates that complex formation in the presence of fibrin will be delayed, allowing a burst of enzyme activity following plasmin generation, but a tight, pseudoirreversible complex will result eventually. Chymotrypsin is more weakly inhibited by alpha 2-antiplasmin, exhibiting an overall Ki' of 0.1 nM, after two-stage complex formation. The inhibition constant for the initial loose complex (Ki) is very similar for both enzymes. The difference in binding strength between the two enzymes is accounted for by the dissociation rate constant of the second step of complex formation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1703440     DOI: 10.1021/bi00218a014

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  13 in total

Review 1.  The plasminogen activator/plasmin system.

Authors:  J D Vassalli; A P Sappino; D Belin
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

2.  Stopped-flow fluorescence kinetics of bovine alpha 2-antiplasmin inhibition of bovine midiplasmin.

Authors:  S Christensen; L Sottrup-Jensen; U Christensen
Journal:  Biochem J       Date:  1995-01-01       Impact factor: 3.857

3.  Interaction of subtilisins with serpins.

Authors:  T Komiyama; H Grøn; P A Pemberton; G S Salvesen
Journal:  Protein Sci       Date:  1996-05       Impact factor: 6.725

4.  Interaction of activated protein C with serpins.

Authors:  J M Hermans; S R Stone
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

5.  An examination of the inhibitory mechanism of serpins by analysing the interaction of trypsin and chymotrypsin with alpha 2-antiplasmin.

Authors:  J J Enghild; Z Valnickova; I B Thøgersen; S V Pizzo; G Salvesen
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

6.  Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.

Authors:  J M Edelberg; S V Pizzo
Journal:  Biochem J       Date:  1992-08-15       Impact factor: 3.857

7.  Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.

Authors:  Tilman M Hackeng; Kristin M Seré; Guido Tans; Jan Rosing
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-17       Impact factor: 11.205

Review 8.  The plasminogen-plasmin system in malignancy.

Authors:  H C Kwaan
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 9.  Tumor invasion, proteolysis, and angiogenesis.

Authors:  U P Thorgeirsson; C K Lindsay; D W Cottam; D E Gomez
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 10.  Serpins in thrombosis, hemostasis and fibrinolysis.

Authors:  J C Rau; L M Beaulieu; J A Huntington; F C Church
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.